Novel Therapeutic Strategies Target Chemoresistance Mechanisms in Small Cell Lung Cancer
Key Insights
Two independent research teams have identified distinct molecular pathways driving chemotherapy resistance in small cell lung cancer, offering new therapeutic targets for this aggressive disease with a five-year survival rate of only 7%.
Professor Chao Zhang's team developed a DNA nanomachine that delivers PRMT1 (search) inhibitor DCLX069 followed by cisplatin in a programmed sequence, targeting the PRMT1/SOX2 (search) signaling axis that drives tumor stemness and chemoresistance.
Researchers led by Professor Liu Qingsong discovered that the BMX (search)-E2F1 (search) pathway promotes chemoresistance and developed compound IHMT-15137 (search), which when combined with cisplatin showed strong anti-tumor effects in drug-resistant cancer models.
Two groundbreaking research initiatives have unveiled novel therapeutic strategies to combat chemotherapy resistance in small cell lung cancer (SCLC), a highly aggressive malignancy with limited treatment options and poor patient outcomes. The studies, conducted by teams at Southern Medical University and the Chinese Academy of Sciences, identify distinct molecular mechanisms driving resistance and present innovative solutions that could transform treatment approaches for this challenging cancer type.
DNA Nanomachine Targets Tumor Stemness
Professor Chao Zhang's team at Zhujiang Hospital, Southern Medical University, has developed a sophisticated DNA nanomachine-based drug delivery system that addresses chemoresistance through temporal programming of therapeutic release. The researchers identified the PRMT1 (search)/SOX2 (search) signaling axis as a critical driver of chemotherapy resistance in SCLC, with PRMT1 being markedly upregulated in chemoresistant cells and closely correlated with poor patient prognosis.
The innovative nanomachine simultaneously loads the PRMT1 (search) inhibitor DCLX069 and cisplatin, enabling a programmed therapeutic sequence within tumor cells. The system first rapidly releases DCLX069 to suppress tumor stemness, followed by gradual release of cisplatin to maximize cytotoxic efficacy. Mechanistic studies revealed that PRMT1 promotes chemoresistance by activating SOX2 (search)-mediated tumor stemness, and inhibition of PRMT1 significantly reduced stemness while enhancing sensitivity to cisplatin.
In cellular and animal models, the DNA nanomachine effectively reversed chemoresistance in SCLC and significantly inhibited tumor growth. Notably, compared with conventional intravenous cisplatin administration, the nanomachine markedly reduced cisplatin-associated hematological and renal toxicity without inducing obvious immunogenic responses, demonstrating a favorable biosafety profile.
BMX-E2F1 Pathway Emerges as Resistance Target
Parallel research led by Professor Liu Qingsong from the Hefei Institutes of Physical Science identified the BMX (search)-E2F1 (search) pathway as another crucial mechanism underlying chemotherapy resistance. The team discovered that BMX and E2F1 proteins, which are linked to cell growth and survival, show high activity in tumor samples and drug-resistant cancer cells.
The researchers found that BMX (search) helps stabilize E2F1 (search), allowing cancer cells to continue growing, repairing damage, and spreading even under chemotherapy pressure. This process plays a key role in making cancer resistant to treatment. Based on these findings, they developed compound IHMT-15137 (search), which specifically blocks BMX activity and disrupts downstream signals while reducing E2F1 levels.
Laboratory tests demonstrated that when used in combination with cisplatin, IHMT-15137 (search) produced strong anti-tumor effects in drug-resistant cancer cells and patient-derived tumor models. The combination treatment slowed tumor growth, triggered cancer cell death, and showed minimal side effects in animal studies.
Clinical Implications and Future Directions
These complementary approaches address the urgent need for new treatment strategies in SCLC, where most patients are diagnosed at advanced stages and quickly develop resistance to standard chemotherapy. With a five-year survival rate of approximately 7%, SCLC represents one of the most challenging malignancies in oncology.
The DNA nanomachine strategy offers particular promise due to the high programmability of DNA-based materials, potentially enabling extension to other chemoresistant tumor types and adaptation for multi-target and personalized precision therapies. Professor Zhang's team noted that with further optimization of structural design, dosing regimens, and scalable manufacturing processes, the platform could advance toward clinical application.
Associate Professor Qi Shuang, commenting on the BMX (search)-E2F1 (search) research, stated: "Our findings suggest a new way to overcome chemotherapy resistance in small cell lung cancer by targeting key proteins early in the pathway."
Both research teams have demonstrated that targeting fundamental resistance mechanisms—whether through tumor stemness pathways or cell survival signaling—can restore chemosensitivity and improve therapeutic outcomes. These discoveries provide new avenues for developing combination therapies that could significantly impact treatment success rates in this devastating disease.